AI Terminal

MODULE: AI_ANALYST

Interactive Q&A, Risk Assessment, Summarization

MODULE: DATA_EXTRACT

Excel Export, XBRL Parsing, Table Digitization

MODULE: PEER_COMP

Sector Benchmarking, Sentiment Analysis

SYSTEM ACCESS LOCKED

Authenticate / Register Log In

Orion Oyj

Legal Proceedings Report • Oct 20, 2010

3232_rns_2010-10-20_e7aff46c-07f2-4168-ae8d-d2934bc8ea70.html

Legal Proceedings Report

Open in Viewer

Opens in native device viewer

Disclosure 281782

Orion - Company Announcement

European Medicines Agency has initiated the review of Orion´s dexmedetomidine marketing authorisation application

ORION CORPORATION STOCK EXCHANGE RELEASE 20 October 2010 AT 4.15 PM EET Orion Corporation has submitted a marketing authorisation application for the intensive care sedative agent dexmedetomidine for the evaluation by the European Medicines Agency (EMA), the pharmaceutical regulatory authority for the EU countries. EMA has announced today that it has validated the centralised marketing authorisation application and initiated the review. The review time for a centralised marketing authorisation application typically exceeds one year. Orion Corporation Timo Lappalainen Reijo Salonen President and CEO SVP, Research and Development Contact person: Reijo Salonen, SVP, Research and Development, phone +358 50 966 3647 Publisher: Orion Corporation Communications Orionintie 1A, FI-02200 Espoo www.orion.fi [HUG#1453555]